8-K: Carisma Therapeutics Announces Third Quarter 2024 Financial Results and Provides Business Update

Carisma Therapeutics reported its third quarter 2024 financial results, highlighting progress in its clinical and preclinical programs, including upcoming data presentations and development candidate nominations.

Summary

• Carisma Therapeutics announced its financial results for the third quarter of 2024, ending September 30, 2024.
• The company's cash and cash equivalents totaled $26.9 million as of September 30, 2024, compared to $40.4 million at the end of the previous quarter.
• Research and development expenses for the quarter were $11.3 million, a decrease from $19.6 million in the same period of 2023, primarily due to a revised operating plan.
• General and administrative expenses decreased to $5.2 million from $6.6 million in the same quarter of the previous year.
• The net loss for the quarter was $12.7 million, compared to a net loss of $21.4 million for the same period in 2023.
• Carisma expects its current cash reserves to fund operations into the third quarter of 2025.
• The company anticipates initial results from the Phase 1 study of CT-0525 in the first quarter of 2025.
• A development candidate for the liver fibrosis program is also expected to be nominated in the first quarter of 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is progress in clinical programs and cost-cutting measures, the significant decrease in cash and ongoing losses temper the positive aspects. The company is still in a high-risk phase of development.

Positives

• The company's research and development expenses decreased by $8.3 million year-over-year due to a revised operating plan.
• General and administrative expenses decreased by $1.4 million year-over-year.
• The net loss decreased to $12.7 million from $21.4 million in the same quarter of the previous year.
• The company has made progress in its clinical and preclinical programs, with key milestones expected in the first quarter of 2025.
• Carisma has expanded its collaboration with Moderna to include two research targets for autoimmune diseases.

Negatives

• Cash and cash equivalents decreased from $40.4 million at the end of the previous quarter to $26.9 million.
• The company experienced a net loss of $12.7 million for the quarter.
• The company halted further development of CT-0508 and paused development of CT-1119 as part of its revised operating plan.
• The company implemented a workforce reduction as part of its revised operating plan.

Risks

• The company's cash forecast contains estimates and assumptions, and variances could impact the company's liquidity prior to the third quarter of 2025.
• There are risks associated with the company's ability to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs.
• The company faces risks related to regulatory requirements, clinical trial designs, and the ability to replicate positive results from preclinical studies in later clinical trials.
• The company's ability to realize the anticipated benefits of its pipeline reprioritization and corporate restructuring is uncertain.

Future Outlook

Carisma anticipates that its cash and cash equivalents of $26.9 million as of September 30, 2024 are sufficient to sustain its planned operations into the third quarter of 2025. The company expects to report initial data from the Phase 1 study of CT-0525 and nominate a development candidate for its liver fibrosis program in the first quarter of 2025.

Management Comments

• Steven Kelly, President and CEO of Carisma Therapeutics, stated that the company's recent progress across clinical and preclinical programs demonstrates their commitment to pioneering therapies that address significant unmet medical needs.
• He also mentioned that they are advancing on multiple fronts and expect to report initial data from the Phase 1 study of CT-0525 in the first quarter of 2025.

Industry Context

This announcement reflects the ongoing development and financial challenges faced by clinical-stage biopharmaceutical companies. The focus on innovative immunotherapies and collaborations with companies like Moderna is consistent with current trends in the biotech industry. The company's focus on cell therapies for solid tumors and autoimmune diseases aligns with areas of high unmet medical need and significant research interest.

Comparison to Industry Standards

• The decrease in R&D spending is a common strategy for biotech companies looking to extend their cash runway, especially in the current economic climate. Companies like Adaptimmune and Allogene have also implemented similar cost-cutting measures.
• The cash runway projection into Q3 2025 is typical for companies at this stage, but the actual runway will depend on the pace of clinical trials and the success of fundraising efforts. Companies like Iovance and Nkarta have similar cash runway projections.
• The focus on CAR-M therapies is a relatively new area compared to CAR-T therapies, and the results of Carisma's clinical trials will be closely watched by the industry. Companies like Caribou Biosciences are also exploring novel cell therapy approaches.
• The collaboration with Moderna is a significant development, as it leverages Moderna's mRNA technology. This is similar to other biotech companies partnering with larger pharmaceutical companies to accelerate development and commercialization.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the decrease in cash and the ongoing losses, but encouraged by the progress in clinical programs.
• Employees may be affected by the workforce reduction implemented as part of the revised operating plan.
• Customers and partners may be interested in the progress of the clinical trials and the potential for new therapies.
• Creditors may be monitoring the company's financial situation and cash runway.

Next Steps

• Carisma expects to report initial data from the Phase 1 study of CT-0525 in the first quarter of 2025.
• The company plans to nominate a development candidate for its liver fibrosis program in the first quarter of 2025.
• Carisma will present new preclinical data at the SITC and AASLD meetings in November 2024.

Key Dates

Keywords

CAR-Monocyte, Immunotherapy, Cell Therapy, Oncology, Liver Fibrosis, Autoimmune Disease, Clinical Trial, Preclinical Data, Moderna, CT-0525, Hepatocellular Carcinoma, Financial Results